CA1093971A - Carcinostatic composition and method of treating a malignant condition - Google Patents

Carcinostatic composition and method of treating a malignant condition

Info

Publication number
CA1093971A
CA1093971A CA273,441A CA273441A CA1093971A CA 1093971 A CA1093971 A CA 1093971A CA 273441 A CA273441 A CA 273441A CA 1093971 A CA1093971 A CA 1093971A
Authority
CA
Canada
Prior art keywords
benzaldehyde
inclusion compound
cyclodextrin
composition
carcinostatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA273,441A
Other languages
English (en)
French (fr)
Inventor
Setsuo Takeuchi
Mutsuyuki Kochi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microsemi Semiconductor ULC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of CA1093971A publication Critical patent/CA1093971A/en
Expired legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA273,441A 1976-03-09 1977-03-08 Carcinostatic composition and method of treating a malignant condition Expired CA1093971A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2522576A JPS52108027A (en) 1976-03-09 1976-03-09 Anticarcinogen
JP25225/1976 1976-03-09

Publications (1)

Publication Number Publication Date
CA1093971A true CA1093971A (en) 1981-01-20

Family

ID=12160014

Family Applications (1)

Application Number Title Priority Date Filing Date
CA273,441A Expired CA1093971A (en) 1976-03-09 1977-03-08 Carcinostatic composition and method of treating a malignant condition

Country Status (9)

Country Link
US (1) US4983636A (en:Method)
JP (1) JPS52108027A (en:Method)
AU (1) AU499475B2 (en:Method)
BE (1) BE852283A (en:Method)
CA (1) CA1093971A (en:Method)
DE (1) DE2710327C3 (en:Method)
FR (1) FR2343475A1 (en:Method)
GB (1) GB1573965A (en:Method)
NL (1) NL172917C (en:Method)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5446001U (en:Method) * 1977-09-07 1979-03-30
JPS5830032B2 (ja) * 1981-02-18 1983-06-27 呉羽化学工業株式会社 ビフイダス菌の増殖剤
JPS6112623A (ja) * 1984-06-28 1986-01-21 Kaken Pharmaceut Co Ltd エンケフアリナ−ゼ阻害剤
JPS6256423A (ja) * 1985-09-06 1987-03-12 Kaken Pharmaceut Co Ltd 悪液質治療改善剤
GB8705780D0 (en) * 1987-03-11 1987-04-15 Norsk Hydro As Anticancer compounds
AT393221B (de) * 1988-02-03 1991-09-10 Leopold Pharma Gmbh Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
JPH0269540A (ja) * 1988-09-05 1990-03-08 Chisso Corp 結晶性ポリオレフイン組成物
US5330744A (en) * 1988-11-14 1994-07-19 Sloan-Kettering Institute For Cancer Research Method for increasing sensitivity to chemically induced terminal differentiation
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
US5789189A (en) * 1993-09-24 1998-08-04 The Regents Of The University Of California Inhibition of cyst formation by cytoskeletal specific drugs
GB2298791B (en) * 1995-03-13 1999-05-05 Stepan Co Methods and compositions for disinfecting surfaces containing tuberculosis causing bacteria
EA007649B1 (ru) * 1999-09-08 2006-12-29 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Ингибиторы гистондеацетилазы, вызывающие дифференцировку клеток, и их применение
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
WO2002078451A1 (en) * 2001-03-30 2002-10-10 Premier Botanicals Ltd. Pesticidal compositions from prunus
AU2004228011A1 (en) * 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
JP6898072B2 (ja) * 2015-08-27 2021-07-07 秀行 佐谷 １４−３−３タンパク質活性調節剤
JP7054085B2 (ja) * 2016-06-30 2022-04-13 Ｓｈｉｏｄａライフサイエンス株式会社 バラ科サクラ属に属する植物の葉の抽出液を含有する抗腫瘍剤
JP6541087B1 (ja) * 2018-10-16 2019-07-10 株式会社ワールドナッツ アーモンドペースト組成物
JP7018531B1 (ja) * 2021-04-30 2022-02-10 潤 齋藤 Ａｘｌ阻害剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827452A (en) * 1955-05-31 1958-03-18 Univ Minnesota Stabilization of materials

Also Published As

Publication number Publication date
DE2710327A1 (de) 1977-09-15
DE2710327B2 (de) 1980-04-17
NL172917C (nl) 1983-11-16
FR2343475B1 (en:Method) 1980-04-25
FR2343475A1 (fr) 1977-10-07
DE2710327C3 (de) 1981-02-12
AU2307377A (en) 1978-09-14
NL172917B (nl) 1983-06-16
AU499475B2 (en) 1979-04-26
GB1573965A (en) 1980-08-28
JPS52108027A (en) 1977-09-10
NL7702535A (nl) 1977-09-13
BE852283A (fr) 1977-09-09
JPS54962B2 (en:Method) 1979-01-18
US4983636A (en) 1991-01-08

Similar Documents

Publication Publication Date Title
CA1093971A (en) Carcinostatic composition and method of treating a malignant condition
JP2824917B2 (ja) 抗腫瘍剤
JPS62228026A (ja) 免疫増強剤
CN1198161A (zh) 含蝶呤衍生物的活性氧消除剂
CN110746598A (zh) 一种可完全降解的gsh/ros双敏感聚合物及其制备方法和应用
KR950008767B1 (ko) 에브셀렌(Ebselen)의 새로운 의약적 용도
KYOTANI et al. A study of embolizing materials for chemo-embolization therapy of hepatocellular carcinoma: antitumor effect of cis-diamminedichloroplatinum (II) albumin microspheres, containing chitin and treated with chitosan on rabbits with VX2 hepatic tumors
AU2018348892B2 (en) Formulation containing A-decarbonized-5a androstane compound for increasing white blood cell and use thereof
JPS6115840A (ja) 免疫賦活剤
AU769882B2 (en) Medicament containing platinum complex compounds and the use thereof
US5710179A (en) Antitumor agent
CN115025088A (zh) 十氢萘吡啶酮生物碱及其药物组合物的应用
CN115645365A (zh) 一种复方氟尿嘧啶注射液及其制备方法
JP2773895B2 (ja) ダナゾール組成物
US4882314A (en) A composition and method of treating selected malignant conditions
CN114948927B (zh) 一种含亚苄基的3-苯并呋喃酮衍生物在制备抗肿瘤药物中的应用
CN1137682C (zh) 一种治疗剂
CA2193838A1 (en) Disease preventive/remedy
CN101786976A (zh) 硒巯代半胱氨酸苯甲酰胺类化合物及其制备方法和其应用
CN111568890A (zh) 绿原酸、同分异构体或药学上可接受的盐在制备肿瘤化疗增敏药物中的应用
CA1095415A (en) Carcinostatic composition and method of treating a malignant condition
JPH0534338B2 (en:Method)
CN120478357A (zh) Azd2423在制备治疗实体瘤的药物中的应用
JPS638923B2 (en:Method)
JPS5936884B2 (ja) 制癌剤

Legal Events

Date Code Title Description
MKEX Expiry